Gliomas are a diverse group of primary central nervous system neoplasms with no curative
therapies available. Brain macrophages comprise microglia in the brain parenchyma, border …

Glioblastoma (GBM) is one of the most lethal malignancies in humans. Even after surgical
resection and aggressive radio‐or chemotherapies, patients with GBM can survive for less …

Background Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM)
and have been implicated in promoting tumor progression and immunosuppression …

Background High infiltration of tumor-associated macrophages (TAMs) is associated with
tumor promotion and immunosuppression. The triggering receptor expressed on myeloid …

Background Radioresistance and immune escape are crucial reasons for unsatisfactory
therapeutic effects of glioblastoma (GBM). Although triggering receptor expressed on …

Chemodynamic therapy (CDT) has shown promising antitumor effects in various malignant
tumors. However, its application for glioblastoma (GBM) is significantly hindered by the …

Triggering receptor expressed on myeloid cells 2 (TREM-2), a glycosylated receptor
belonging to the immunoglobin superfamily and especially expressed in the myeloid cell …

Cancer immunotherapy has recently emerged as a key strategy for cancer treatment.
TREM2, a key target for regulating the tumor immune microenvironment, is important in …

Chemodynamic therapy (CDT) has garnered significant attention for treating diverse
malignant tumours due to its minimally invasive nature, reduced damage to healthy tissues …

Glioblastoma multiforme (GBM) is one of the deadliest human cancers with very limited
treatment options available. The malignant behavior of GBM is manifested in a tumor which …